Society for Immunotherapy of Cancer (SITC) posted on LinkedIn:

“SITC is proud to share that the Journal for ImmunoTherapy of Cancer (JITC) has reached an Impact Factor of 10.6 and a CiteScore of 17.8 in 2024!

As an open access, peer-reviewed journal, JITC is committed to serve as a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.

Explore the latest high-impact articles:

1. Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC.

Authors: Gyeong Dae Kim, So-I Shin, Pureum Sun, Jeong Eun Lee, Chaeuk Chung, Yea Eun Kang, Da Hyun Kang, Jihwan Park

2. EZH2 inhibition and 5-azacytidine enhance antitumor immunity in PTEN-deficient glioblastoma by activation viral mimicry response.

Authors: Dandan Zhu, Zeying Li, Huolun Feng, Jiabin Zheng, Xiao Xiao, Zuda Huang, Liangying Zheng, Jieqing Guo, Fa Ling, Yong Li, Fan Xing

3. Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy.

Authors: Salomé S. Pinho, Matthew S. Macauley, Heinz Läubli

4. Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors.

Authors: Alia D Zander, Rossin Erbe, Yan Liu, Ailin Jin, Seung Won Hyun, Sayantoni Mukhopadhyay, Ben Terdich, Mario G Rosasco, Nirali Patel, Brett M Mahon, A Kate Sasser, Michelle A Ting-Lin, Halla Nimeiri, Justin Guinney, Douglas Adkins, Matthew Zibelman, Kyle A Beauchamp, Chithra Sangli, Michelle M Stein, Timothy Taxter, Timothy Chan, Sandip P Patel, Ezra E W Cohen.”

More posts featuring Society for Immunotherapy of Cancer.

SITC – JITC Has Reached an Impact Factor of 10.6 and a CiteScore of 17.8 in 2024!